BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids. It is derived from a sequence found in human gastric juice and is classified as a gastric pentadecapeptide. BPC-157 has been the subject of extensive preclinical research — predominantly in animal models — exploring its potential roles in tissue repair, mucosal protection, and various wound-healing processes.

Despite growing interest from athletes, wellness communities, and some clinicians, BPC-157 has not been approved for human use by any regulatory authority. It has no completed randomized controlled trials in humans, and its safety profile in people remains largely unknown. The FDA has classified BPC-157 as a Category 2 bulk drug substance, restricting its use in pharmaceutical compounding.

The majority of BPC-157 research has been conducted in laboratory (in vitro) and animal (in vivo) settings. Preclinical studies have investigated its effects in areas including gastrointestinal mucosal healing and ulcer models, tendon, ligament, muscle, and bone injury models, inflammatory pathways and wound-healing mechanisms, and vascular and neurological injury models.

A 2025 systematic review in orthopedic sports medicine literature synthesized the available preclinical evidence and noted that while animal data show promise for musculoskeletal applications, clinical safety data in humans are extremely limited. Only a small number of pilot-scale human studies have been published, none of which are large-scale randomized controlled trials. No pharmaceutical company has initiated an FDA clinical trial program for BPC-157 as of early 2026, partly because the compound's naturally occurring sequence makes it difficult to patent.